Abstract ATP-sensitive K + (K ATP ) channel mutations have been identiWed in individuals with dilated cardiomyopathy and overt heart failure. Here, a common E23K functional polymorphism in the Kir6.2 channel pore versus cardiac phenotype was studied in a cross-sectional community-based cohort (n = 2,031). The KK genotype was associated with greater left ventricular size among subjects with increased stress load due to hypertension. These Wndings implicate Kir6.2 K23 as a risk factor for adverse subclinical myocardial remodeling, and underscore the signiWcance of cardiac K ATP channels within the population.
Introduction
Susceptibility or resistance to heart failure, despite apparently similar risk load, is attributable to individual variation in homeostatic reserve (Bleumink et al. 2004) . Ventricular cardiomyocytes are rich in stress-responsive K ATP channels comprised pore-forming Kir6.2 and SUR2A regulatory subunits encoded by KCNJ11 and ABCC9, respectively (Zingman et al. 2002; Yamada et al. 2006) . Their critical role in stress adaptation is exempliWed by genetically defective channel complexes caused by ABCC9 mutations in human dilated cardiomyopathy (Bienengraeber et al. 2004) and Kcnj11 ¡/¡ mice, vulnerable to hypertension-induced heart failure .
A common single nucleotide polymorphism (67G > A) in human KCNJ11 corresponds to glutamic acid or lysine at residue 23 of Kir6.2 (Riedel et al. 2005) . Abnormal channel gating for the K23 variant has been reported, with altered activation and inhibition sensitivity proWles recorded in vitro for various ligands such as adenine nucleotides, long chain acyl CoA esters, and protons (Riedel et al. 2005; Li et al. 2005) , Consequently, this functional polymorphism impairs the ability of K ATP channels to respond properly to the cellular milieu. Case-control and case-cohort studies have demonstrated association between E23K and susceptibility to glucose intolerance and diabetes (Riedel et al. 2005; Fischer et al. 2008) , as Kir6.2 also forms K ATP channels in insulin-producing pancreatic beta-cells. Here, we explored the relationship between this K ATP channel polymorphism and subclinical heart disease in the community.
Materials and methods

Subjects
A community-based cross-sectional cohort of 2,031 predominantly Caucasian adults residing in Olmsted County, Minnesota, was studied (RedWeld et al. 2003) , under a protocol approved by the Mayo Clinic Institutional Review Board. Individuals were age 45 years or older with detailed clinical and prospective cardiac structure/function data, and stored DNA samples. Hypertension was deWned as systolic blood pressure¸140 mmHg or diastolic blood pressure9 0 mmHg at the time of echocardiography, irrespective of clinical diagnosis or treatment of hypertension. Left ventricular (LV) measurements were determined by M-mode and 2D biplane echocardiography, and indexed to body surface area.
Genotyping
Genomic DNA comprising the 67A>G KCNJ11 variant was ampliWed by the polymerase chain reaction and digested with BanII. Resultant fragments, varying in size based on presence (67G) or absence (67A) of a BanII restriction site, were resolved on agarose gels to assign genotypes.
Statistical analyses
The association of genotype with echocardiographic parameters was analyzed using analysis of variance (ANOVA). The synergistic eVects between genotype and LV mass in association with LV dimensions were evaluated by introducing an interaction term into the model.
Results
Clinical characteristics of the study cohort reXected the composition of Olmsted County, Minnesota, community members age 45 years or older (RedWeld et al. 2003) . In brief, 48% of participants were males, the mean age was 62.8 § 10.6 years, and the mean body mass index was 28.4 § 5.41 kg/m 2 . Prevalence of diagnosed disease was congestive heart failure 2.6%, coronary artery disease 12.2%, previous myocardial infarction 4.8%, hypertension 29%, and diabetes 4.5%. Genotype frequencies were in Hardy-Weinberg equilibrium (EE = 44%; EK = 47%; KK = 9%) and similar to previously reported control populations (Riedel et al. 2005 ). In the group at large, there was no signiWcant association between genotypes and measures of cardiac structure/function (LV dimensions, mass, and ejection fraction), electrical instability (atrial and ventricular arrhythmias), or metabolism (fasting glucose, diabetes, and body mass index) at enrollment. Among individuals with documented hypertension at the time of echocardiography (n = 1,187), the KK genotype was signiWcantly associated with greater LV dimension and volume in both diastole and systole (Table 1) . A synergistic eVect on LV size of KK genotype and LV mass, a marker of chronic cardiac stress load (Fig. 1) , further validated the impact of Kir6.2 E23K on cardiac structure in hypertension.
Discussion
Hypertension is the most common risk factor for congestive heart failure, and LV enlargement is an established precursor of symptomatic ventricular dysfunction (Kannel et al. 1972; Vasan et al. 1997 ). The Kir6.2 K23 allele, present in over half the population, is here implicated as a risk factor for transition from hypertensive stress load to subclinical maladaptive cardiac remodeling. Intact K ATP channels function as high-Wdelity homeostatic rheostats that adjust membrane potential-dependent functions to match cellular energetic demand. Genetic or pharmacologic alterations predicted to abnormally increase or decrease the channel open probability have been reported to uncouple this metabolic signal decoding function, and thereby compromise cardiac stress responsiveness and increase susceptibility to heart disease (Bienengraeber et al. 2004; Kane et al. 2006; Yamada et al. 2006; Lee et al. 2007 ). Our Wndings with the K23 allele of the Kir6.2 pore, consistent with previous work with the ABCC9-encoded regulatory subunit (Olson et al. 2007) , uncover an interactive K ATP channel gene-environment substrate that confers cardiac disease risk in a predominantly Caucasian population. Determining the overall impact of Kir6.2 E23K across ethnic groups and on long-term clinical outcome, i.e., progression to LV enlargement and clinical heart failure, will require further study.
